← Back to Clinical Trials
Recruiting NCT04751760

NCT04751760 Feasibility Study of a New Immunoglobulin E (IgE) Assay Method

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04751760
Status Recruiting
Phase
Sponsor University Hospital, Toulouse
Condition Allergy and Immunology
Study Type OBSERVATIONAL
Enrollment 1,376 participants
Start Date 2021-04-20
Primary Completion 2026-04-20

Eligibility & Interventions

Sex All sexes
Min Age 6 Months
Max Age 99 Years
Study Type OBSERVATIONAL
Interventions
collection of blood and urine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,376 participants in total. It began in 2021-04-20 with a primary completion date of 2026-04-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objective is to study the feasibility of a new specific IgE assay using a bioluminescence technique in a pediatric and adult allergic population. For this, we will collect blood, and urine during a blood test scheduled for the follow-up of the patient.

Eligibility Criteria

Inclusion Criteria: * Males or females 6 months' old or older * Sensitization or allergy towards a trophallergen, an aeroallergen, hymenoptera venom or drug proven by: * positive skin test (s) * and / or IgE specific (s)\> 0.1 kUA / L * and / or anamnesis in favor of an allergic reaction of mediated IgE * Social coverage up to date Exclusion Criteria: * Children younger than 6 months'old * Children's weight less than 10 kg * Pregnant or breastfeeding women * Patients with cystic fibrosis * Patients with dysimmune or autoimmune pathology * Anamnesis in favor of a delayed allergy or a contact allergy.

Contact & Investigator

Central Contact

Marine Michelet, MD

✉ michelet.m@chu-toulouse.fr

📞 33-5 34 55 85 85

Principal Investigator

Marine Michelet, MD

PRINCIPAL INVESTIGATOR

University Hospital, Toulouse

Frequently Asked Questions

Who can join the NCT04751760 clinical trial?

This trial is open to participants of all sexes, aged 6 Months or older, up to 99 Years, studying Allergy and Immunology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04751760 currently recruiting?

Yes, NCT04751760 is actively recruiting participants. Contact the research team at michelet.m@chu-toulouse.fr for enrollment information.

Where is the NCT04751760 trial being conducted?

This trial is being conducted at Toulouse, France, Toulouse, France.

Who is sponsoring the NCT04751760 clinical trial?

NCT04751760 is sponsored by University Hospital, Toulouse. The principal investigator is Marine Michelet, MD at University Hospital, Toulouse. The trial plans to enroll 1,376 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology